[
    {
      "title": "BYSTOLIC",
      "Molecule_Name": "NEBIVOLOL HYDROCHLORIDE",
      "Therapeutic_Area": "Cardiovascular",
      "Corporation": "ALLERGAN SALES LLC",
      "CRP_Ranking": "15",
      "ATC3_Code": [
        "C07AB Beta Blocking Agents"
      ],
      "Indication": "Hypertension",
      "Licensing_Status": "Licensed to china",
      "Product_Market_Size": [
        {
          "country": "US",
          "value": "982,128,912"
        },
        {
          "country": "China",
          "value": "882,821,789"
        },
        {
          "country": "JAPAN",
          "value": "736,429,663"
        }
      ],
      "CAGR": "7 %",
      "Forecast": [
        {
          "country": "US",
          "value": "-42%"
        },
        {
          "country": "China",
          "value": "-30%"
        },
        {
          "country": "JAPAN",
          "value": "20%"
        }
      ],
      "Sales_Contribution": [
        {
          "country": "US",
          "value": "70%"
        },
        {
          "country": "China",
          "value": "40%"
        },
        {
          "country": "JAPAN",
          "value": "30%"
        }
      ],
      "BrandSharevsTherapyClass": [
        {
          "country": "US",
          "value": "30"
        },
        {
          "country": "China",
          "value": "50"
        },
        {
          "country": "JAPAN",
          "value": "70"
        }
      ],
      "MoleculeSharevsTherapyClass": [
        {
          "country": "US",
          "value": "30"
        },
        {
          "country": "China",
          "value": "20"
        },
        {
          "country": "JAPAN",
          "value": "10"
        }
      ],
      "licensing": [
        {
          "country": "US",
          "License": "NA",
          "LOE": "2.5 years",
          "registration": "Approved"
        },
        {
          "country": "CN",
          "License": "NA",
          "LOE": "3.5 years",
          "registration": "In registration"
        },
        {
          "country": "JP",
          "License": "NA",
          "LOE": "4 years",
          "registration": "Approved"
        }
      ]
    },
    {
      "title": "FINACEA",
      "Molecule_Name": "AZELAIC ACID",
      "Therapeutic_Area": "",
      "Corporation": "ALLERGAN SALES LLC",
      "CRP_Ranking": "25",
      "ATC3_Code": [
        "D10AX Other anti-acne preparations for topical use"
      ],
      "Indication": "",
      "Licensing_Status": "Licensed to china",
      "licensing": [
        {
          "country": "US",
          "License": "License US",
          "LOE": "2.5 years",
          "registration": "In registration"
        },
        {
          "country": "CN",
          "License": "License CN",
          "LOE": "3.5 years",
          "registration": "In registration"
        },
        {
          "country": "JP",
          "License": "License JP",
          "LOE": "4 years",
          "registration": "In registration"
        }
      ],
      "Product_Market_Size": [
        {
          "country": "US",
          "value": "892,281,129"
        },
        {
          "country": "China",
          "value": "228,281,879"
        },
        {
          "country": "JAPAN",
          "value": "361,429,366"
        }
      ],
      "CAGR": "9 %",
      "Forecast": [
        {
          "country": "US",
          "value": "-32%"
        },
        {
          "country": "China",
          "value": "-20%"
        },
        {
          "country": "JAPAN",
          "value": "30%"
        }
      ],
      "Sales_Contribution": [
        {
          "country": "US",
          "value": "60%"
        },
        {
          "country": "China",
          "value": "50%"
        },
        {
          "country": "JAPAN",
          "value": "40%"
        }
      ],
      "BrandSharevsTherapyClass": [
        {
          "country": "US",
          "value": "40"
        },
        {
          "country": "China",
          "value": "60"
        },
        {
          "country": "JAPAN",
          "value": "80"
        }
      ],
      "MoleculeSharevsTherapyClass": [
        {
          "country": "US",
          "value": "40"
        },
        {
          "country": "China",
          "value": "30"
        },
        {
          "country": "JAPAN",
          "value": "20"
        }
      ]
    },
    {
      "title": "HALOBETASOL PROPIONATE",
      "Molecule_Name": "HALOBETASOL PROPIONATE",
      "Therapeutic_Area": "",
      "Corporation": "ALLERGAN SALES LLC",
      "CRP_Ranking": "30",
      "ATC3_Code": [
        "S01AX Other antiinfectives"
      ],
      "Indication": "",
      "Licensing_Status": "Licensed to USA",
      "licensing": [
        {
          "country": "US",
          "License": "License US",
          "LOE": "2.5 years",
          "registration": "In registration"
        },
        {
          "country": "CN",
          "License": "License CN",
          "LOE": "3.5 years",
          "registration": "In registration"
        },
        {
          "country": "JP",
          "License": "License JP",
          "LOE": "4 years",
          "registration": "In registration"
        }
      ],
      "Product_Market_Size": [
        {
          "country": "US",
          "value": "882,228,712"
        },
        {
          "country": "China",
          "value": "682,824,798"
        },
        {
          "country": "JAPAN",
          "value": "367,249,366"
        }
      ],
      "CAGR": "11 %",
      "Forecast": [
        {
          "country": "US",
          "value": "-52%"
        },
        {
          "country": "China",
          "value": "-20%"
        },
        {
          "country": "JAPAN",
          "value": "40%"
        }
      ],
      "Sales_Contribution": [
        {
          "country": "US",
          "value": "40%"
        },
        {
          "country": "China",
          "value": "30%"
        },
        {
          "country": "JAPAN",
          "value": "20%"
        }
      ],
      "BrandSharevsTherapyClass": [
        {
          "country": "US",
          "value": "50"
        },
        {
          "country": "China",
          "value": "70"
        },
        {
          "country": "JAPAN",
          "value": "90"
        }
      ],
      "MoleculeSharevsTherapyClass": [
        {
          "country": "US",
          "value": "30"
        },
        {
          "country": "China",
          "value": "50"
        },
        {
          "country": "JAPAN",
          "value": "40"
        }
      ]
    },
    {
      "title": "KETOCONAZOLE",
      "Molecule_Name": "KETOCONAZOLE",
      "Therapeutic_Area": "",
      "Corporation": "ALLERGAN SALES LLC",
      "CRP_Ranking": "35",
      "ATC3_Code": [
        "D01AC Imidazole and triazole derivatives",
        "G01AF Imidazole derivatives",
        "J02AB Imidazole derivatives"
      ],
      "Indication": "",
      "Licensing_Status": "Licensed to UK",
      "licensing": [
        {
          "country": "US",
          "License": "License US",
          "LOE": "2.5 years",
          "registration": "In registration"
        },
        {
          "country": "CN",
          "License": "License CN",
          "LOE": "3.5 years",
          "registration": "In registration"
        },
        {
          "country": "JP",
          "License": "License JP",
          "LOE": "4 years",
          "registration": "In registration"
        }
      ],
      "Product_Market_Size": [
        {
          "country": "US",
          "value": "485,528,129"
        },
        {
          "country": "China",
          "value": "885,721,785"
        },
        {
          "country": "JAPAN",
          "value": "562,429,365"
        }
      ],
      "CAGR": "6 %",
      "Forecast": [
        {
          "country": "US",
          "value": "-52%"
        },
        {
          "country": "China",
          "value": "-20%"
        },
        {
          "country": "JAPAN",
          "value": "40%"
        }
      ],
      "Sales_Contribution": [
        {
          "country": "US",
          "value": "40%"
        },
        {
          "country": "China",
          "value": "30%"
        },
        {
          "country": "JAPAN",
          "value": "20%"
        }
      ],
      "BrandSharevsTherapyClass": [
        {
          "country": "US",
          "value": "50"
        },
        {
          "country": "China",
          "value": "70"
        },
        {
          "country": "JAPAN",
          "value": "90"
        }
      ],
      "MoleculeSharevsTherapyClass": [
        {
          "country": "US",
          "value": "20"
        },
        {
          "country": "China",
          "value": "25"
        },
        {
          "country": "JAPAN",
          "value": "35"
        }
      ]
    },
    {
      "title": "MINOXIDIL (FOR WOMEN)",
      "Molecule_Name": "MINOXIDIL",
      "Therapeutic_Area": "",
      "Corporation": "ALLERGAN SALES LLC",
      "CRP_Ranking": "45",
      "ATC3_Code": [
        "C02DC Pyrimidine derivatives",
        "D11AX Other dermatologicals"
      ],
      "Indication": "",
      "Licensing_Status": "Licensed to Japan",
      "licensing": [
        {
          "country": "US",
          "License": "License US",
          "LOE": "2.5 years",
          "registration": "In registration"
        },
        {
          "country": "CN",
          "License": "License CN",
          "LOE": "3.5 years",
          "registration": "In registration"
        },
        {
          "country": "JP",
          "License": "License JP",
          "LOE": "4 years",
          "registration": "In registration"
        }
      ],
      "Product_Market_Size": [
        {
          "country": "US",
          "value": "985,285,963"
        },
        {
          "country": "China",
          "value": "258,821,879"
        },
        {
          "country": "JAPAN",
          "value": "963,254,365"
        }
      ],
      "CAGR": "5 %",
      "Forecast": [
        {
          "country": "US",
          "value": "-58%"
        },
        {
          "country": "China",
          "value": "-25%"
        },
        {
          "country": "JAPAN",
          "value": "45%"
        }
      ],
      "Sales_Contribution": [
        {
          "country": "US",
          "value": "45%"
        },
        {
          "country": "China",
          "value": "50%"
        },
        {
          "country": "JAPAN",
          "value": "55%"
        }
      ],
      "BrandSharevsTherapyClass": [
        {
          "country": "US",
          "value": "55"
        },
        {
          "country": "China",
          "value": "65"
        },
        {
          "country": "JAPAN",
          "value": "75"
        }
      ],
      "MoleculeSharevsTherapyClass": [
        {
          "country": "US",
          "value": "25"
        },
        {
          "country": "China",
          "value": "30"
        },
        {
          "country": "JAPAN",
          "value": "40"
        }
      ]
    },
    {
      "title": "ADVAIR HFA",
      "Molecule_Name": "FLUTICASONE PROPIONATE",
      "Therapeutic_Area": "",
      "Corporation": "GLAXO GRP LTD",
      "CRP_Ranking": "25",
      "ATC3_Code": [
        "D07AC Corticosteroids, potent (group III)",
        "R01AD Corticosteroids",
        "R03BA Glucocorticoids"
      ],
      "Indication": "ADVAIR HFA is indicated for the twice-daily treatment of asthma in patients aged 12 years and older. ADVAIR HFA should be used for patients not adequately controlled on a long-term asthma control medication such as an inhaled corticosteroid (ICS) or whose disease warrants initiation of treatment with both an ICS and long-acting beta2-adrenergic agonist (LABA).",
      "Licensing_Status": "Licensed to US",
      "licensing": [
        {
          "country": "US",
          "License": "License US",
          "LOE": "2.5 years",
          "registration": "In registration"
        },
        {
          "country": "CN",
          "License": "License CN",
          "LOE": "3.5 years",
          "registration": "In registration"
        },
        {
          "country": "JP",
          "License": "License JP",
          "LOE": "4 years",
          "registration": "In registration"
        }
      ],
      "Product_Market_Size": [
        {
          "country": "US",
          "value": "902,148,942"
        },
        {
          "country": "China",
          "value": "872,871,789"
        },
        {
          "country": "JAPAN",
          "value": "734,119,763"
        }
      ],
      "CAGR": "8 %",
      "Forecast": [
        {
          "country": "US",
          "value": "-40%"
        },
        {
          "country": "China",
          "value": "-25%"
        },
        {
          "country": "JAPAN",
          "value": "25%"
        }
      ],
      "Sales_Contribution": [
        {
          "country": "US",
          "value": "50%"
        },
        {
          "country": "China",
          "value": "25%"
        },
        {
          "country": "JAPAN",
          "value": "25%"
        }
      ],
      "BrandSharevsTherapyClass": [
        {
          "country": "US",
          "value": "20"
        },
        {
          "country": "China",
          "value": "30"
        },
        {
          "country": "JAPAN",
          "value": "40"
        }
      ],
      "MoleculeSharevsTherapyClass": [
        {
          "country": "US",
          "value": "70"
        },
        {
          "country": "China",
          "value": "60"
        },
        {
          "country": "JAPAN",
          "value": "40"
        }
      ]
    },
    {
      "title": "BEVESPI AEROSPHERE",
      "Molecule_Name": "FORMOTEROL FUMARATE",
      "Therapeutic_Area": "",
      "Corporation": "ASTRAZENECA PHARMS",
      "CRP_Ranking": "19",
      "ATC3_Code": [
        "R03AC Selective beta-2-adrenoreceptor agonists"
      ],
      "Indication": "BEVESPI AEROSPHERE is a combination of glycopyrrolate and formoterol fumarate indicated for the long-term, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.",
      "Licensing_Status": "Licensed to china",
      "licensing": [
        {
          "country": "US",
          "License": "License US",
          "LOE": "2.5 years",
          "registration": "In registration"
        },
        {
          "country": "CN",
          "License": "License CN",
          "LOE": "3.5 years",
          "registration": "In registration"
        },
        {
          "country": "JP",
          "License": "License JP",
          "LOE": "4 years",
          "registration": "In registration"
        }
      ],
      "Product_Market_Size": [
        {
          "country": "US",
          "value": "955,428,942"
        },
        {
          "country": "China",
          "value": "872,841,779"
        },
        {
          "country": "JAPAN",
          "value": "737,729,553"
        }
      ],
      "CAGR": "3 %",
      "Forecast": [
        {
          "country": "US",
          "value": "-40%"
        },
        {
          "country": "China",
          "value": "-20%"
        },
        {
          "country": "JAPAN",
          "value": "10%"
        }
      ],
      "Sales_Contribution": [
        {
          "country": "US",
          "value": "30%"
        },
        {
          "country": "China",
          "value": "70%"
        },
        {
          "country": "JAPAN",
          "value": "40%"
        }
      ],
      "BrandSharevsTherapyClass": [
        {
          "country": "US",
          "value": "20"
        },
        {
          "country": "China",
          "value": "40"
        },
        {
          "country": "JAPAN",
          "value": "60"
        }
      ],
      "MoleculeSharevsTherapyClass": [
        {
          "country": "US",
          "value": "70"
        },
        {
          "country": "China",
          "value": "10"
        },
        {
          "country": "JAPAN",
          "value": "20"
        }
      ]
    },
    {
      "title": "ALVESCO",
      "Molecule_Name": "CICLESONIDE",
      "Therapeutic_Area": "",
      "Corporation": "COVIS PHARMA BV",
      "CRP_Ranking": "35",
      "ATC3_Code": [
        "R03BA Glucocorticoids",
        "R01AD Corticosteroids"
      ],
      "Indication": "ALVESCO is indicated for the maintenance treatment of asthma as prophylactic therapy in adult and adolescent patients 12 years of age and older.",
      "Licensing_Status": "Licensed to Japan",
      "licensing": [
        {
          "country": "US",
          "License": "License US",
          "LOE": "2.5 years",
          "registration": "In registration"
        },
        {
          "country": "CN",
          "License": "License CN",
          "LOE": "3.5 years",
          "registration": "In registration"
        },
        {
          "country": "JP",
          "License": "License JP",
          "LOE": "4 years",
          "registration": "In registration"
        }
      ],
      "Product_Market_Size": [
        {
          "country": "US",
          "value": "982,100,912"
        },
        {
          "country": "China",
          "value": "100,821,789"
        },
        {
          "country": "JAPAN",
          "value": "736,469,663"
        }
      ],
      "CAGR": "10 %",
      "Forecast": [
        {
          "country": "US",
          "value": "-50%"
        },
        {
          "country": "China",
          "value": "-20%"
        },
        {
          "country": "JAPAN",
          "value": "13%"
        }
      ],
      "Sales_Contribution": [
        {
          "country": "US",
          "value": "75%"
        },
        {
          "country": "China",
          "value": "49%"
        },
        {
          "country": "JAPAN",
          "value": "36%"
        }
      ],
      "BrandSharevsTherapyClass": [
        {
          "country": "US",
          "value": "43"
        },
        {
          "country": "China",
          "value": "75"
        },
        {
          "country": "JAPAN",
          "value": "68"
        }
      ],
      "MoleculeSharevsTherapyClass": [
        {
          "country": "US",
          "value": "40"
        },
        {
          "country": "China",
          "value": "16"
        },
        {
          "country": "JAPAN",
          "value": "76"
        }
      ]
    },
    {
      "title": "ASMANEX HFA",
      "Molecule_Name": "MOMETASONE FUROATE",
      "Therapeutic_Area": "",
      "Corporation": "MERCK SHARP DOHME",
      "CRP_Ranking": "35",
      "ATC3_Code": [
        "D07AC Corticosteroids, potent (group III)",
        "D07XC Corticosteroids, potent, other combinations",
        "R01AD Corticosteroids",
        "R03BA Glucocorticoids"
      ],
      "Indication": "ASMANEXÂ® HFA is indicated for the maintenance treatment of asthma as prophylactic therapy in patients 12 years of age and older.",
      "Licensing_Status": "Licensed to US",
      "licensing": [
        {
          "country": "US",
          "License": "License US",
          "LOE": "2.5 years",
          "registration": "In registration"
        },
        {
          "country": "CN",
          "License": "License CN",
          "LOE": "3.5 years",
          "registration": "In registration"
        },
        {
          "country": "JP",
          "License": "License JP",
          "LOE": "4 years",
          "registration": "In registration"
        }
      ],
      "Product_Market_Size": [
        {
          "country": "US",
          "value": "112,128,912"
        },
        {
          "country": "China",
          "value": "222,421,789"
        },
        {
          "country": "JAPAN",
          "value": "465,429,663"
        }
      ],
      "CAGR": "4 %",
      "Forecast": [
        {
          "country": "US",
          "value": "-50%"
        },
        {
          "country": "China",
          "value": "-70%"
        },
        {
          "country": "JAPAN",
          "value": "30%"
        }
      ],
      "Sales_Contribution": [
        {
          "country": "US",
          "value": "50%"
        },
        {
          "country": "China",
          "value": "10%"
        },
        {
          "country": "JAPAN",
          "value": "40%"
        }
      ],
      "BrandSharevsTherapyClass": [
        {
          "country": "US",
          "value": "60"
        },
        {
          "country": "China",
          "value": "70"
        },
        {
          "country": "JAPAN",
          "value": "60"
        }
      ],
      "MoleculeSharevsTherapyClass": [
        {
          "country": "US",
          "value": "70"
        },
        {
          "country": "China",
          "value": "30"
        },
        {
          "country": "JAPAN",
          "value": "60"
        }
      ]
    },
    {
      "title": "ATROVENT",
      "Molecule_Name": "IPRATROPIUM BROMIDE",
      "Therapeutic_Area": "",
      "Corporation": "BOEHRINGER INGELHEIM",
      "CRP_Ranking": "25",
      "ATC3_Code": [
        "R01AX Other nasal preparations",
        "R03BB Anticholinergics"
      ],
      "Indication": "ATROVENT HFA Inhalation Aerosol is indicated as a bronchodilator for maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.",
      "Licensing_Status": "Licensed to china",
      "licensing": [
        {
          "country": "US",
          "License": "License US",
          "LOE": "2.5 years",
          "registration": "In registration"
        },
        {
          "country": "CN",
          "License": "License CN",
          "LOE": "3.5 years",
          "registration": "In registration"
        },
        {
          "country": "JP",
          "License": "License JP",
          "LOE": "4 years",
          "registration": "In registration"
        }
      ],
      "Product_Market_Size": [
        {
          "country": "US",
          "value": "902,000,912"
        },
        {
          "country": "China",
          "value": "873,765,789"
        },
        {
          "country": "JAPAN",
          "value": "836,449,664"
        }
      ],
      "CAGR": "13 %",
      "Forecast": [
        {
          "country": "US",
          "value": "-56%"
        },
        {
          "country": "China",
          "value": "-35%"
        },
        {
          "country": "JAPAN",
          "value": "30%"
        }
      ],
      "Sales_Contribution": [
        {
          "country": "US",
          "value": "60%"
        },
        {
          "country": "China",
          "value": "30%"
        },
        {
          "country": "JAPAN",
          "value": "10%"
        }
      ],
      "BrandSharevsTherapyClass": [
        {
          "country": "US",
          "value": "43"
        },
        {
          "country": "China",
          "value": "36"
        },
        {
          "country": "JAPAN",
          "value": "77"
        }
      ],
      "MoleculeSharevsTherapyClass": [
        {
          "country": "US",
          "value": "35"
        },
        {
          "country": "China",
          "value": "25"
        },
        {
          "country": "JAPAN",
          "value": "16"
        }
      ]
    },
    {
      "title": "VERDESO",
      "Molecule_Name": "DESONIDE",
      "Therapeutic_Area": "",
      "Corporation": "ALLERGAN SALES LLC",
      "CRP_Ranking": "40",
      "ATC3_Code": [
        "A07EA Corticosteroids acting locally",
        "D07AC Corticosteroids, potent (group III)",
        "R01AD Corticosteroids",
        "R03BA Glucocorticoids",
        "D07AB Corticosteroids, moderately potent (group II)",
        "S01BA Corticosteroids, plain",
        "D07BB Corticosteroids, moderately potent, combinations with antiseptics",
        "R03AK Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics"
      ],
      "Indication": "",
      "Licensing_Status": "Licensed to Russia",
      "licensing": [
        {
          "country": "US",
          "License": "License US",
          "LOE": "2.5 years",
          "registration": "In registration"
        },
        {
          "country": "CN",
          "License": "License CN",
          "LOE": "3.5 years",
          "registration": "In registration"
        },
        {
          "country": "JP",
          "License": "License JP",
          "LOE": "4 years",
          "registration": "In registration"
        }
      ],
      "Product_Market_Size": [
        {
          "country": "US",
          "value": "586,128,875"
        },
        {
          "country": "China",
          "value": "658,821,746"
        },
        {
          "country": "JAPAN",
          "value": "635,789,389"
        }
      ],
      "CAGR": "9 %",
      "Forecast": [
        {
          "country": "US",
          "value": "-65%"
        },
        {
          "country": "China",
          "value": "-35%"
        },
        {
          "country": "JAPAN",
          "value": "48%"
        }
      ],
      "Sales_Contribution": [
        {
          "country": "US",
          "value": "50%"
        },
        {
          "country": "China",
          "value": "55%"
        },
        {
          "country": "JAPAN",
          "value": "60%"
        }
      ],
      "BrandSharevsTherapyClass": [
        {
          "country": "US",
          "value": "60"
        },
        {
          "country": "China",
          "value": "65"
        },
        {
          "country": "JAPAN",
          "value": "70"
        }
      ],
      "MoleculeSharevsTherapyClass": [
        {
          "country": "US",
          "value": "34"
        },
        {
          "country": "China",
          "value": "44"
        },
        {
          "country": "JAPAN",
          "value": "54"
        }
      ]
    }
  ]